Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Document › Details

Genomics Medicine Ireland Ltd.. (3/30/17). "Press Release: Genomics Medicine Ireland Announces Two Appointments to Its Board. Dr. Kari Stefánsson and Dr. Paul Saunders Appointed to the Board". Dublin.

Organisations Organisation Genomics Medicine Ireland Ltd. (GMI)
  Group WuXi PharmaTech (Group)
  Organisation 2 deCode Genetics ehf.
  Group Amgen (Group)
Products Product genomics
  Product 2 venture capital
Index term Index term Genomics Medicine Ireland–SEVERAL: investment, 201610 financing round Series A $40m (€36m) incl ISIF + ARCH Ventures + Polaris Partners + GV
Persons Person Stefánsson, Kári (deCODE 200505 CEO)
  Person 2 Saunders, Paul (Ireland (govt) 201610 Head of Innovation at ISIF)

Irish life sciences company Genomics Medicine Ireland Ltd., has today announced the appointment of Dr. Kári Stefánsson and Dr. Paul Saunders to its Board of Directors. The appointment will increase the size of the Genomics Medicine Ireland Board of Directors to six members.

“We are delighted to have Kári Stefánsson and Paul Saunders join our Board of Directors,” said Daniel Crowley, acting CEO, Genomics Medicine Ireland. Dr. Stefánsson, a luminary in the field of genetics, is founder and CEO of deCODE genetics, a groundbreaking genetics company now part of Amgen. Paul Saunders leads the Innovation and Special Investments group at GMI investor, ISIF (Ireland Strategic Investment Fund). “Genomics Medicine Ireland will benefit greatly from the insight and expertise Drs. Stefánsson and Saunders bring to our board,” said Crowley.

With this appointment, the Genomics Medicine Ireland Board of Directors now consists of Daniel Crowley, Paul Thurk, Co-founder of GMI and Managing Director of ARCH Venture Partners Europe, Tom Hulme, General Partner at GV (formerly Google Ventures), Terry McGuire, Founding Partner at Polaris Partners, Paul Saunders, Ireland Strategic Investment Fund and Kári Stefánsson, deCODE genetics.


For media queries please contact:

Celine Crawford
MKC Communications
+353 1 703 8600

Note to the editors:

Kári Stefánsson

Kári Stefánsson, M.D., Dr. Med. founded deCODE genetics in August 1996. He was previously a professor of Neurology, Neuropathology and Neuroscience at Harvard University and Director of Neuropathology at Beth Israel Hospital in Boston, Massachusetts. From 1983 to 1993, he held faculty positions in Neurology, Neuropathology and Neurosciences at the University of Chicago. Dr. Stefánsson received his M.D. and Dr. Med. from the University of Iceland and is board-certified in neurology and neuropathology in the United States. He has shaped deCODE’s scientific approach and been actively engaged in leading its gene discovery work, serving as senior author on most of the company’s publications in major scientific journals. deCODE is now part of Amgen, a founding corporate partner to GMI.

Paul Saunders

Paul Saunders is Head of Innovation and Special Investments for the Ireland Strategic Investment Fund, leading the sovereign fund’s investment agenda targeting large, transformative ‘Big Idea’ opportunities. Prior to joining the fund, Paul worked as Head of Innovation for An Post, as Group Development Director for Greencore, Bioenergy Development Director for NTR and as Senior Consultant with McKinsey and Co in Dublin and London. Paul has a BSc in Physics from Bristol University, a PhD in Physics from Cambridge University and an MBA from Insead.

About Genomics Medicine Ireland Limited

Founded in 2015, Genomics Medicine Ireland Limited (GMI) is an Irish life-sciences company leading large-scale, population-based genome research studies on the island of Ireland examining the relationship between genetics, health and disease. It is building a preeminent disease-specific database of population genomics. GMI works in collaboration with clinicians, patients, academic researchers and global biotech and pharmaceutical sectors to discover pathways to new treatments and new diagnostics for people both here in Ireland and around the world.

GMI’s partners include investors ARCH Venture Partners, Polaris Partners, GV (formerly Google Ventures), the Ireland Strategic Investment Fund, and corporate partner Amgen and its subsidiary deCODE genetics. Collectively, they bring multi-decade experience in disease genomics to GMI.

Record changed: 2017-04-04


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for WuXi PharmaTech (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top